Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05764161 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
A Phase 3 study of Prurigo Nodularis, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT05764161: Completed Phase 3 study of Prurigo Nodularis, sponsored by Incyte Corporation.
NCT05764161 is a Phase 3 study of Prurigo Nodularis that has completed, run by Incyte Corporation. The registered enrollment target is 190 participants, below the 216-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05764161, a Phase 3 study of Prurigo Nodularis, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Primary Outcome
WI-NRS4 was defined as the percentage of participants achieving a ≥4-point improvement (reduction) in Worst-Itch Numeric Rating Scale (WI-NRS) score from baseline. The WI-NRS is a patient-reported outcome comprised of a single item rated on a scale from 0 ("no itch") to 10 ("worst imaginable itch"). Participants assessed their worst level of prurigo nodularis-related itch during the past 24 hours on a scale of 0 to 10. The WI-NRS score for baseline was determined by averaging the 7 daily WI-NRS
Conditions Studied
Interventions
- DRUG Ruxolitinib Cream
- DRUG Vehicle Cream
Study Locations (20)
New South Wales
- Premier Specialists Pty Ltd - Kogarah
- Liverpool Hospital - Liverpool
- Holdsworth House Medical Practice - Sydney
- Westmead Hospital - Sydney
California
- Dermatology Research Associates - Los Angeles
- Clinical Science Institute Clinical Research Specialists Inc - Santa Monica
- Cura Clinical Research - Sherman Oaks
Ohio
- Oakview Dermatology - Athens
- Aventiv Research Inc-Dublin - Dublin
- Wright State Physicians, Inc. - Fairborn
Pennsylvania
- University of Pittsburgh Medical Center Upmc Dermatology Clinic Oakland Falk Medical Building - Pittsburgh
- Dermdox Center For Dermatology - Sugarloaf
Alabama
- University of Alabama At Birmingham - Birmingham
Arkansas
- Northwest Arkansas Clinical Trials Center - Arkansas City
Florida
- Ars - Maitland Clinical Research Unit - Orlando
Georgia
- Marietta Dermatology the Skin Cancer Center Marietta - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2023-06-12 |
| Est. Completion | 2025-11-04 |
| Phase | Phase 3 |
What the finished NCT05764161 record still lists
NCT05764161 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 216-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (12% lower).
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib Cream is the first listed.
NCT05764161 names 20 study sites across 12 states, led by New South Wales, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT05764161 about?
NCT05764161 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)". The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
What is the current status of trial NCT05764161?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2023-06-12. Estimated completion is 2025-11-04.
What conditions does trial NCT05764161 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT05764161?
The interventions under investigation include: Ruxolitinib Cream (DRUG), Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT05764161?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05764161 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05764161's enrollment target sits among peer trials
190 7th of 14 higher than 8 of 14 other Prurigo Nodularis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prurigo Nodularis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI